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ABSTRACT 
Hematopoietic Stem Cells (HSCs) are cells that have the ability to self-renewal and differentiate into all of 
hematopoietic lineages. The lack of donors and unavailable efficient protocols for ex vivo expansion of HSCs, 
are obstacles in successful cell therapies. MicroRNAs (also refer as miRNAs or miRs) have significant roles in 
hematopoiesis; they can effect on HSCs expansion, maintaining undifferentiated state, self-renewal and differen-
tiation. Recently attentions have been given to these small regulatory molecules to utilize them in order to ex-
pand HSCs. Using bioinformatics analysis we identified Sall4 as putative target of miR-15b and miR-219-5p. 
Relative expression levels of miRNAs and Sall4 were evaluated by qRT-PCR. Here we show 247-fold and 4.2-
fold increasing Sall4 expression level compared to control group in CD34+ cells nucleofected by anti-miR-15b 
and anti-miR-219-5p, respectively. These data showed that anti-miR-15b can promote clonogenic capacity of 
HSCs and also we found that miR-15b alone was able to increase the number of CD34+HSCs in vitro by more 
than 2 fold by targeting Sall4. Moreover, level of CD34 marker in HSCs nucleofected by anti-miR-15b increased 
more than 50 %. Our analysis showed no statistically difference in mRNA level of Sall4 after nucleofection of 
anti-miR-219-5p. Sall4 is a factor capable of enhancing HSC expansion significantly. We demonstrated that in-
hibition of miR-15b can enhance ex vivo expansion of UCB-derived HSCs and also expression of Sall4 allowed 
expansion and preserve self- renewal of CD34+ HSCs.  
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INTRODUCTION 
HSCs are multipotent stem cells which 
reside in specialized microenvironments 
(niches) in the bone marrow (BM) and de-
fined by two properties: self-renewal capaci-
ty and multilineage repopulation ability 
(Metcalf, 2007). HSCs are forefront of clini-
cal application of stem cells therapy. There 
are two major problems in HSCs transplanta-
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tion; low accessibility of suitable human leu-
kocyte antigen (HLA)–matched donors; and 
the small number stem cells (umbilical cord 
blood (UCB)) (Csaszar et al., 2012). Isola-
tion HSCs from cord blood is a therapeutic 
method for patients with haematological dis-
orders such as leukemias, lymphomas, solid 
tumors, anemias (sickle cell anaemia). 
The main disadvantage of UCB-derived 
HSCs in clinical application is the small 
number of these precious cells in a single 
unit (Barker, 2007; Metcalf, 2007).To over-
come this problem, many studies have been 
tried to offer the ways that improve the self-
renewal potential and ex vivo expansion of 
HSCs. 
 Generally, protocols for ex vivo expan-
sion of HSCs are based on manipulation of 
external signaling (using cytokine) (Metcalf, 
2008) or internal signaling (by gene therapy 
techniques). While the cytokine based proto-
cols showed some advantages (e.g. improve 
in vitro proliferation of HSCs), they are frus-
trating due to induction of HSCs differentia-
tion (Audet et al., 2002). However, protocols 
that influence intrinsic regulators are more 
promising. These regulators are included 
transcription factors, epigenetic mechanisms, 
miRNAs and long non-coding RNAs 
(lncRNAs) (Sauvageau et al., 2004; Walasek 
et al., 2012).  
MiRNAs are non-coding RNAs (~22nt 
length) that down-regulate target gene ex-
pression at the post-transcriptional level by 
binding to the 3 ′ untranslated region (UTRs) 
or coding sequence of their corresponding 
mRNAs (Tay et al., 2008), resulting in de-
creased levels of the corresponding protein 
or cleavage of the RNA (Zhang et al., 2012). 
However, some miRNAs bind to promoter 
and induce gene expression, a mechanism 
that called miRNA-mediated RNA activation 
(Huang et al., 2012). Studies have signified 
the importance of miRNAs in regulation of 
various biological processes such as devel-
opment, proliferation, apoptosis and differ-
entiation (Zimmerman and Wu, 2011).  
One of the important factors involved in 
self-renewal and maintenance of HSCs mul-
tipotency of CD34 stem cells is Sall4 tran-
scription factor (TF) (Aguila et al., 2011). 
Sall4 is zinc-finger TF belong to spalt-1ike 
protein family, located on chromosome 20 
and expressed in undifferentiated stem cells 
like normally embryonic stem cells (ESCs) 
and CD34+ HSCs (Tay et al., 2008). Sall4 
binds to regulatory regions of ESCs master 
regulators such as Nanog and Oct-4 and reg-
ulates their expression (Wu et al., 2006; 
Zhang et al., 2006; Tan et al., 2013). This TF 
is crucial for embryo development and has 
an important role in preserving of self-
renewal in mesenchymal stem cells (MSC) 
and HSCs. Moreover, expression of Sall4 re-
presses during differentiation with other plu-
ripotency related genes and is going to ex-
press pluripotency genes. Recently, Sall4 is 
known as important factor in expansion pro-
cess in of HSCs (Zhang et al., 2006; Aguila 
et al., 2011).  
In current study, by using bioinformatics 
analysis we identified Sall4 as putative target 
of miR-15b and miR-219-5p and showed 
that UCB-derived HSCs bearing two anti-
miRs for miR-15b and miR-219-5p exhibit 
enhanced expansion efficiently in vitro. 
 
MATERIALS AND METHODS 
Immunomagnetic separation and cell  
culture 
UCB was prepared from Iranian Blood 
Transfusion Organization. Mononuclear cells 
were isolated from UCB by Ficoll-Paque 
PLUS (GE Healthcare) density gradient cen-
trifugation. The MACS indirect CD34 Mi-
croBead Kit (human-Miltenyi Biotec) was 
used to separate CD34+HSCs according to 
the manufacturer’s instructions. Afterwards, 
CD34+HSCs were collected and transferred 
into serum-free Stemline II expansion medi-
um (Sigma-Aldrich) supplemented with 
50 ng/ml TPO, 50 ng/dl SCF, 50 ng/dl Flt-3, 
2 mmol/l l-glutamine and 1x antibiotics. 
 
Flow cytometry 
The purity of CD34+ HSCs was evaluat-
ed by Flow cytometry. Cells were incubated 
with phycoerythrin (PE)-conjugated anti-
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CD34 antibodies (Miltenyi Biotec) for 
45 min at 4 °C. Mouse IgG1was used as iso-
type control. Evaluation of CD34+ cells also 
were performed in days 7 and 10 . 
 
Plasmid preparation and nucleofection 
Lenti-miR-Off-GFP-hsa-miR-15b vector 
(anti-miR-15b), Lenti-miR-Off-GFP-hsa-
miR-219-5p vector (anti-miR-219-5p) and 
pLenti-III-GFP-mir-Off control vector (abm 
Inc., Canada) were purchased from ABM In-
corporation. Bacterial colonies were grown 
in LB-ampicillin broth by incubation with 
shaking at 37 °C overnight. Then plasmids 
were extracted using the DNA purification 
kit (DNA-spin, iNtRON Biotechnology, 
Seoul, Korea). 
Nucleofection of CD34+HSCs was per-
formed according to the manufacturer’s in-
structions with the nucleofector machine 
(Lonza). Cells (8×105) were resuspended in 
100 μL of HSCs nucleofection solution 
(Lonza), and 5 μg of anti hsa-miR-15b, 5 μg 
of anti miR-219-5b, and 5 μg of control 
scramble vector (abm Inc., Canada) was ad-
ded. Samples were transferred into certified 
cuvettes (Lonza) and transfected by nu-
cleofection with program U-008. Fresh me-
dium (500 μL) was added immediately after 
transfection to each cuvette, and the cells 
were plated and incubated at 37 °C for 
10 days.After nucleofection, HSCs were 
stained with 0.4 % Trypan Blue (vital dye) 
(Sigma-Aldrich) for 1 min at room tempera-
ture and the number of live HSCs (un-
stained) were counted every 48 hours using a 
hemocytometer. 
 
Colony forming unit assay 
The clonogenic capacity was evaluated 
before and after expansion by colony form-
ing unit (CFU) assay. Approximately 1500 
cells were mixed in 2 ml of methocult H4435 
(Stem Cell Technology). Then plates incu-
bated at 37 °C for 14 days. The number of 
colony CFU was counted after 14 day using 
an inverted microscope.  
 
RNA extraction and qRT-PCR for mRNA 
Total RNA was extracted with Trizol 
(Invitrogen). Reverse transcription was per-
formed using a M-MuLV RT Master Mix kit 
(CinnaGen Co.). The cDNA were subjected 
to qRT-PCR using SYBR Premix Ex Taq II 
(Takara Bio Inc.). β-actin mRNA in each 
sample was quantified as an endogenous 
control. The relative expression levels of 
Sall4 were calculated using the 2-ΔΔCt meth-
od. The primers used were: Sall4  
(forward 5'- GGCGGAGAGGGCAAA-
TAACT -3',  
reverse 5'-CACTGGAGCACCCAGCTC-3'), 
β-actin  
(forward 5'-
TGAAGATCAAGATCATTGCTCCC-3', 
reverse 5'-
AGTCATAGTCCGCCTAGAAGC-3'). 
 
RNA extraction and qRT-PCR for miRNA 
Total RNA was extracted with Trizol 
(Invitrogen). Reverse transcription was per-
formed using a miRNA 1st-Strand cDNA 
Synthesis Kit (Stratagene; Agilent Technol-
ogies, Inc.). The cDNA were subjected to 
qRT-PCR (EvaGreen-based qRT-PCR) us-
ing High-Specificity miRNA qRT-PCR De-
tection Kit (Stratagene; Agilent Technolo-
gies, Inc.). The relative expression levels of 
miRNAs were normalized to U6 snRNA as 
an endogenous control and were calculated 
using the 2-ΔΔCt method. The primers used 
were: hsa-miR-219-5p  
(forward 5'-
CTGATTGTCCAAACGCAATTCT-3'), 
hsa-miR-15b  
(forward 5'-
CTAGCAGCACATCATGGTTTACA -3'), 
U6  
(forward 5'-
AAATTGGAACGATACAGAGAAG-3'). 
 
Statistical analysis 
All measurements were done in tripli-
cate. Statistical analyses were performed by 
GraphPad Software (GraphPad PRISM V 
5.0analytical Software). Data means were 
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compared using one-way ANOVAs. Statisti-
cal significance was defined at P < 0.05. 
 
RESULTS 
Evaluation of efficacy of nucleofection by 
GFP Vector 
To further show the role of hsa-miR-15b 
and hsa-miR-219-5p in HSCs, nucleofection 
of the HSCs was done by anti-miR-15b, anti-
miR-219-5p and control vector. Nucleofec-
tion efficiency was evaluated by EclipseTE-
2000 Fluorescent microscope (Nikon tech-
nologies). More than 75 % of HSCs were 
nucleofected by pmax-GFP vector after 48 
hours post nucleofection (Figure 1). 
 
Effects of anti hsa-miR-15b and anti miR-
219-5p on ex vivo expansion of CD34+ cells 
To clarify, whether down-regulation of 
miR-15b and miR-219-5p could lead to up-
regulation of Sall4 and eventually promote 
CD34+ HSCs expansion, cells were trans-
fected with anti-miR-15b, anti-miR-219-5p 
and control vector using nucleofection tech-
nique.MiR-15b and miR-219-5p was pre-
dicted to induce hematopoietic differentia-
tion due to targeting Sall4 in different levels. 
The purity of CD34+ cells was evaluated 
by flow cytometry in days 0, 7 and 10. The 
percentage of CD34+ Cells was nearly 91 % 
after immunomagnetic separation (Figure 2). 
Then, we compared percentage of CD34+ 
cells to our groups in days 7 and 10. The 
highest level of CD34 marker belonged to 
the anti-miR-15b group that was 70 % and 
55 % in days 7 and 10, respectively (Figure 
2). 
The percentage of CD34 marker in cells 
treated by anti-miR-219-5p (24 % and 11 % 
in days 7 and 10, respectively) was lower 
than control group in both days (33 % and 
16 % in days 7 and 10, respectively) (Figure 
2). 
HSCs viability and total cell counts were 
determined at every 48 hours by trypan blue 
exclusion and it was always above 80 %. 
HSCs nucleofected with anti-miR-15b ex-
panded 2.3 fold (P < 0.001) and anti-miR-
219-5p 1.5 fold (P < 0.05) compared to those 
nucleofected with control vector (Figure 3). 
Based on the results of flow cytometry for 
expansion marker CD34, in anti-miR-219-5p 
group, we resulted that this effect was not a 
result of self-renewal effects on HSCs. Inter-
estingly, inhibition of miR-15b expression 
with anti-miR redounded Sall4 expression 
that was concurrent with rises in HSCs ex-
pansion. 
 
 
 
 
Figure 1: Nucleofection of HSCs. Nucleofection efficiency was 75 % using pmax-GFP vector for the 
HSCs 48 hours post nucleofection. Magnification,×200 
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Figure 2: Flow cytometry results. Released data (A-G) is one of 3 repetitions. Purity of CD34+ HSCs 
in Day 0 (A); Percentage of CD34+cells in control vector group in day 7 (B)and day 10 (C); Percentage 
of CD34+cells in anti-miR-15b group in day 7 (D)and day 10 (E);Percentage of CD34+cells in anti-miR-
219-5p group in day 7 (F)and day 10 (G);Graph shows percentage of CD34+cells in days 0, 7 and 10 
after nucleofection in 3 repetitions. Values are shown as mean ± SEM (H). 
 
 
 
Figure 3: Bar graph shows total cell counts. Total cell counts were determined at every 48 hours. Val-
ues are shown as mean ± SEM. Statistically different values of *P < 0.05 and **P < 0.01 and 
***P < 0.001 are determined compared with the control. 
 
 
Hematopoietic colony formation assay 
Clonogenic capacity of HSCs was evalu-
ated before and after expansion. As shown in 
Figure 4, the number of CFCs increased on 
average 1.6-fold (P= 0.039) in nucleofected 
HSCs by anti-miRNA-15b.HSCs treated 
with vector control(P=0.539) and anti-miR-
219-5p (P=0.407) showed no statistically 
significant difference in the clonogenic ca-
pacity (Figure 4).These data demonstrate that 
anti-miR-15b can promote clonogenic capac-
ity of HSCs. 
 
Effects of anti-miR-15b and anti miR-219-
5p on Sall4 expression  
As biological significance of miRNA re-
lies on inhibition their gene targets, we ana-
lyzed the predicted targets of hsa-miR15b 
and hsa-miR-219-5p. The analysis was per-
formed by using three algorithms, mirBase, 
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miRanda and TargetScan commonly used to 
predict human miRNA gene targets. We 
found that the expression of Sall4 showed an 
inverse correlation with the expression of 
hsa-miR-15b and hsa-miR-219-5p in CD34+ 
HSCs. We hypothesized hsa-miR-15b and 
hsa-miR-219-5p have potential for targeting 
Sall4.As predicted by mirBase, 3' UTR of 
Sall4 had complementary sequence for has-
miR-15b and has-miR-219-5p seed se-
quence. 
To assert whether hsa-miR-15b and hsa-
219-5p efficacy could retrieveSall4expres-
sion, anti-miR-15b and anti-miR-219-5p 
were nucleofected in CD34+ HSCs. Expres-
sion levels of Sall4 were detected by qRT-
PCR. 
Real-time PCR showed that anti-miR-
15b and anti-miR-219-5p can rectify Sall4 
down-regulation, resulted in an increase in 
cell growth compared with control.  
Anti-miR-15b and anti-miR-219-5p in-
crease 247.3 fold (P < 0.001) and 4.2 fold 
(P=0.08) Sall4 expression in comparison to 
control group, respectively (Figure 5) but the 
difference in Sall4 expression in anti-miR-
219-5p group is not statistically significant. 
These results indicate that down-regulation 
of hsa-miR-15b and consequently up regula-
tion of Sall4 lead to in the expansion of pri-
mary HSCs .Based on our analyses, miR-15b 
targets Sall4 mRNA and reduced its expres-
sion in HSCs.  
Moreover, qRT-PCR was performed for 
miRNAs in order to ensure that anti-
miRNAs work specifically. Relative expres-
sion levels of miR-15b and miR-219-5p in 
comparison to control group showed in Fig-
ure 5A. 
 
 
 
Figure 4: Numbers of colony forming units in different groups after 14 days. (A) Burst-Forming Unit–
Erythroid(BFU-E); (B) CFU- Granulocyte, Erythrocyte, Monocyte/macrophage, Megakaryocyte (CFU-
GEMM); (C) CFU-Granulocyte-Macrophage (CFU-GM); Magnification,×100. (D) Bar graph shows the 
number of CFC in different groups after 14 days; Values are shown as mean ± SEM. Statistically dif-
ferent values of *P < 0.05 and **P < 0.01 and ***P < 0.001 are determined compared to the before 
group. 
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Figure 5: Bar graphs show relative expression levels of miRNAs and Sall4 gene. (A) The relative ex-
pression levels of miR-15b in HSCs treated by anti-miR-15bwas 0.1-fold (P < 0.001) and the relative 
expression levels of miR-219-5p in HSCs treated by anti-miR-219-5p was 0.25-fold (P < 0.001) in 
comparison to control group; (B) The relative expression levels of Sall4 in HSCs treated by anti-miR-
15b and anti-miR-219-5p increase 247.3 (P < 0.001) and 4.2-fold (P=0.08) Sall4 expression in com-
parison to control group, respectively. Values are shown as mean ± SEM. Statistically different values 
of *P < 0.05 and **P < 0.01 and ***P < 0.001 are determined compared with the control. 
 
 
DISCUSSION 
The process of hematopoiesis involves 
HSCs self-renewal and lineage commitment 
procedures which are regulated by extrinsic 
factors (bone marrow microenvironment, cell 
adhesion molecules, growth factors and cy-
tokines) (Zhu and Emerson, 2002) and in-
trinsic factors (signalling networks and tran-
scription factors) (Akala and Clarke, 2006). 
miRNAs is known as a novel regulatory 
molecules in hematopoiesis by targeting in-
trinsic factors involved in hematopoiesis, can 
effect on HSCs expansion, maintaining self-
renewal, differentiation, apoptosis and other 
biology processes (Bissels et al., 2012; 
Favreau and Sathyanarayana, 2012). Recent-
ly, deregulation of miRNAs has been shown 
in leukemia that is linked to breakpoint re-
gions associated with chromosome aberra-
tions in leukemias (Zimmerman and Wu, 
2011). 
Recently, researchers reported miRNAs 
have roles on the expansion of HSCs. Yang 
et al. (2013) showed that miR-17 highly ex-
pressed on hematopoietic progenitors. The 
expression of miR-17 is sought on CD34+ 
human HSCs and found that significantly 
down-regulated while differentiation into 
monocytes and mature megakaryocytes. 
Moreover they reported that expansion of 
cord blood CD34+ cell can be partly aug-
mented by osteoblastic miR-17, and ectopic 
miR-17 can lead to specific expansion of the 
erythroid lineage through promoting HIF-1a 
in osteoblasts. Han et al. (2010) suggested 
that miR-29a may regulate self-renewal in 
HS/PCs (Hematopoietic stem/progenitor 
cells).  
Ooi et al. (2010) reported that in the im-
mature hematopoietic system, mir-125b is 
anti-apoptotic and augments expansion of 
HCSs. Moreover they showed miR-125b in-
creased HSC engraftment transplants by in-
hibiting expression of two anti-apoptotic tar-
get genes, Bmf (Bcl2 modifying factor) and 
KLF13 (Krueppel-like factor 13) and they 
resulted that this effect was a result of self-
renewal effects on HSC (not committed pro-
genitors) (Ooi et al., 2010). 
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In the study on tongue cancer, Sun et al. 
(2011) showed that one of the target proteins 
of miR-15b is Bmi-1 which is involved in 
pluripotency of stem cells. Moreover, studies 
showed one of the Sall4 downstream genes 
is Bmi-1 (Jiang et al., 2009). 
Choong et al. (2007) were reported that 
miR-15b has been up regulated in human 
UCB undergoing erythropoiesis, that is simi-
lar to released data by Lu et al. (2005). Based 
these studies, miR-15b has probably im-
portant role in differentiation especially to 
erythroid lineage that is incompatible with 
our results. 
Rao et al. (2010) demonstrated that over 
expression of miR-219-5p, decreases prolif-
eration and expansion capacity of brain tu-
mor cells. They reported that miR-219-5p 
may have important role in development of 
brain solid tumors (Rao et al., 2010; De Faria 
et al., 2012). Also, miR-219-5p may have 
role in oligodendrocyte differentiation by 
targeting inhibitors of oligodendrocyte dif-
ferentiation such as Sox6 (De Faria et al., 
2012). 
Here, we show that miR-15b and miR-
219-5p target Sall4 and down-regulation 
Sall4 occur upon HSCs differentiation. Bio-
informatics data suggested that 3' UTR of 
Sall4 TF has complementary sequences with 
seed sequences of miR-15b and miR-219-5p. 
So we asked if these two miRNAs target 
Sall4, anti-miRNA for these miRs can re-
verse Sall4 expression and enhance ex vivo 
expansion of UCB-derived HSCs? Two ans-
wer this question, UCB-derived HSCs were 
nucleofected with anti-miRs against miR-
15b and miR-219-5p. Gene expression anal-
ysis with qRT-PCR showed an increase in 
Sall4 expression compared with cells trans-
fected with control vector.  
Flow cytometry for expansion marker, 
CD34, showed elevation level of CD34+ 
HSCs in cells receive anti-miR-15b (more 
than 50 %). It has been suggested that this 
elevation of CD34 level related to express 
Sall4 gene that result in expansion and main-
tain self-renewal probably. 
Furthermore, colony formation carried 
out and data showed 1.6-fold increases in 
colony formation in cells bearing anti-miR-
15b. Although number of cells in anti-miR-
219-5p group were increased, but these cells 
could not maintain their self renewality 
properties. 
Altogether, we indicate that inhibition of 
miR-15b can enhance ex vivo expansion of 
UCB-derived HSCs. Since, the most draw-
backs in transplantation of these cells are 
leakage of cell numbers, our study purposes 
an easy way for promoting in vitro HSCs ex-
pansion. 
Albeit, 3´UTR of miR-219-5p targets 
Sall4 theoretically, but our analysis showed 
no difference in mRNA level of Sall4 after 
nucleofection of anti-miR-219-5p. This data 
suggests that Sall4 probably is not one of the 
miR-219-5p targets however, more analysis 
for confirming this is needed. 
 
CONCLUSION 
Our studies revealed that miR-15b is ex-
pressed in normal HSCs and is up-regulated 
progressively in mature lineages of HSCs 
and during hematopoiesis. Transfection of 
anti-miR-15b in purified HSCs induces ex-
pansion of the HSCs by targeting of Sall4. 
We report an essential role of Sall4 for HSCs 
maintenance and the identification of miR-
15b capable of positively regulating HSCs 
self-renewal at least in part by increasing ex-
pansion levels.  
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